HFE S65C

HFE S65C can help clarify an inherited finding during an iron-overload workup, particularly if you also carry C282Y. Its ability to predict disease is limited. Most people with S65C alone do not develop iron overload, and finding it does not establish why your ferritin is high.

Small clinical studies have linked S65C to mild iron loading, especially in some people who also carry C282Y. Population studies have not consistently found an effect. The American College of Gastroenterology advises that S65C without C282Y does not confer an increased risk of iron overload, although it rates the supporting evidence as very low quality.

What the Variant Changes

HFE provides instructions for a protein involved in regulating iron absorption. S65C changes position 65 of the HFE protein from serine to cysteine. These are two of the building blocks used to make proteins.

Hepcidin is a hormone made by your liver. It limits iron entering the blood from your gut and from cells that store or recycle it. HFE helps regulate that response. In established HFE-related hemochromatosis, hepcidin production can be too low for the amount of stored iron, allowing excess absorption. Human studies demonstrating this problem have mainly involved C282Y-related genotypes; they do not establish the size or mechanism of an S65C effect.

Transferrin saturation is the proportion of your blood's iron-carrying protein occupied by iron. It often rises early in HFE-related iron overload. Ferritin helps assess iron stores, but inflammation and liver injury can also raise it.

What Your Genotype Means

Your result reports whether you carry zero, one, or two copies of S65C. C282Y and H63D are separate variants in the same gene. Their results provide additional context, but each combination needs to be interpreted alongside evidence of iron accumulation.

• One S65C copy without C282Y or H63D: usually has little clinical effect. A raised ferritin still needs an explanation beyond the genetic result.
• Two S65C copies: uncommon and less well studied. This finding alone does not establish hemochromatosis or predict how much iron you will accumulate.
• S65C plus C282Y on opposite gene copies: associated with a low risk of mild iron loading. Some people develop increased liver iron, while many have normal iron tests.
• S65C plus H63D: has not been established as a cause of clinically significant iron overload. Abnormal iron tests warrant evaluation for other causes.

The studies differ in how participants were selected. A referral clinic starts with people whose iron tests are already concerning, so its findings cannot be used as the chance that an otherwise healthy carrier will develop disease.

Liver Damage and Iron Overload

The strongest evidence linking HFE genotypes to liver disease and other complications concerns people with two C282Y copies. A large UK Biobank study of C282Y and H63D found substantial disease risk in the group with two C282Y copies. Those results do not provide risk estimates for S65C.

The small Swedish S65C study found no extensive iron-related liver scarring among the carriers examined. That is reassuring, but it does not prove that serious liver disease can never occur in someone who carries S65C. Alcohol-related liver disease, metabolic fatty liver disease, viral hepatitis, and other inherited disorders remain possible explanations for abnormal liver tests.

A case report described iron overload in a person with S65C and an additional rare HFE change that disrupted processing of the gene's instructions. A targeted S65C result can therefore coexist with another genetic finding that better explains the illness.

What Large Biobanks Found

A 2026 study used Estonian and UK biobank data covering more than 15,800 S65C carriers, but the less common genotype groups were small. Only 32 Estonian participants had two S65C copies. Some S65C combinations were associated with urinary or reproductive diagnoses. One category of prostate disorders was diagnosed about 11 years earlier in Estonian men with two S65C copies or S65C plus another studied HFE variant.

The UK analysis found a different kidney-related diagnosis in only one person with two S65C copies, so it offered limited support for the Estonian finding. These observations do not establish that S65C causes prostate disease or that extra prostate screening improves outcomes.

A separate FinnGen study of more than 420,000 people used recorded blood-removal procedures as an indirect measure of hemochromatosis severity. S65C was associated with fewer recorded procedures after accounting for C282Y, H63D, age, sex, and blood donation history. This association concerns treatment records; it does not establish that S65C protects against organ damage or show why fewer procedures were recorded.

Who Carries It

S65C is more common in populations with European ancestry. A large US health-appraisal study found it less often in the other ancestry groups examined. Frequencies vary between populations, and ancestry alone cannot predict your result.

A negative result excludes this particular variant, not inherited iron overload as a whole. That limitation applies to everyone and matters especially when your family history or iron findings suggest a cause outside the common HFE variants.

When Results Can Be Misleading

• Limited coverage: this result concerns one position in HFE. Other HFE variants and changes in other iron-regulating genes require separate analysis.
• Incomplete genetic context: finding S65C does not show whether you also carry C282Y or H63D. If more than one variant is present, its location on the same or opposite gene copies can affect interpretation.
• Uncertain interpretation: reports can differ in how they classify S65C. A variant of uncertain significance is a DNA change whose effect on disease has not been established. That label alone should not drive treatment.
• Sample-related problems: after a donor stem-cell or bone-marrow transplant, blood DNA may reflect the donor. Genetic changes confined to some blood cells can also complicate an inherited result. These circumstances need a genetics team's advice on sample selection.
• Rare analytical errors: nearby DNA changes, sample contamination, or identification errors can produce an incorrect call. A result that conflicts with other reliable genetic evidence may need confirmation using a different method.
• Consumer DNA interpretations: raw consumer DNA files and third-party interpretations can contain errors. A finding that would change medical care should be confirmed with clinical genetic testing.

A One-Time Result

Your inherited S65C genotype is permanent. Keep a reliable result with your health records; repeating it does not track iron accumulation. Follow-up concerns ferritin, transferrin saturation, and any confirmed cause of iron overload. There is no established S65C-specific schedule that makes annual iron testing necessary for every carrier.